Lambda λ輕鏈(鼠單克隆抗體) 

廣州健侖生物科技有限公司

此抗體和人免疫球蛋白的λ 輕鏈反應(yīng)，和κ 輕鏈無(wú)交叉反應(yīng)?？裳芯繋в?lambda; 輕鏈的B 淋巴細(xì)胞和漿細(xì)胞，細(xì)胞外的免疫球蛋白λ 輕鏈也可著色，應(yīng)注意區(qū)分。研究認(rèn)為B 淋巴細(xì)胞腫瘤的共同特征是只限于單個(gè)輕鏈的表達(dá)，因此κ 和λ 輕鏈可用于良惡性淋巴病變(反應(yīng)性淋巴細(xì)胞增生和淋巴瘤)的研究。

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲(chóng)病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

Lambda λ輕鏈(鼠單克隆抗體) 

【產(chǎn)品介紹】

細(xì)胞定位：細(xì)胞漿

克隆號(hào)：HP6054

同型：IgG

適用組織：石蠟/冰凍

陽(yáng)性對(duì)照：扁桃體

抗原修復(fù)：熱修復(fù)（EDTA）

抗體孵育時(shí)間：30-60min

Lambda λ輕鏈(鼠單克隆抗體) 

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱(chēng)】 廣州健侖生物科技有限公司
【市場(chǎng)部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

Wright博士說(shuō)：“在這一點(diǎn)上，利用端粒酶將有毒產(chǎn)物整合進(jìn)端粒，是非常鼓舞人心的。”
重要的是，和其他許多端粒酶抑制化合物不同，研究人員并沒(méi)有在6-thiodG治療小鼠的血液、肝臟和腎臟中觀察到嚴(yán)重的副作用。
Shay博士說(shuō)：“由于端粒酶在幾乎所有的人類(lèi)腫瘤中表達(dá)，這項(xiàng)工作提出了一種潛在創(chuàng)新的方法，靶定端粒酶表達(dá)的癌細(xì)胞，而對(duì)正常細(xì)胞的毒副作用較小。我們相信這種小分子將填補(bǔ)未知領(lǐng)域中的一個(gè)未曾滿足的癌癥需要，將被迅速應(yīng)用于臨床。”
我們的機(jī)體進(jìn)化出了一些途徑來(lái)擺脫有缺陷的干細(xì)胞。來(lái)自科羅拉多大學(xué)癌癥中心的研究人員在發(fā)表于《干細(xì)胞》(Stem Cells)雜志上的一項(xiàng)研究中揭示，其中一條途徑就是通過(guò)“重編程”使得被輻射損傷的干細(xì)胞分化為不再能夠長(zhǎng)久生存的其他細(xì)胞。輻射會(huì)使得干細(xì)胞喪失它的“干性”。這的確有意義：你不會(huì)希望受損的干細(xì)胞繼續(xù)留在這兒生成受損細(xì)胞。
這項(xiàng)研究還證實(shí)，當(dāng)全身遭受輻射時(shí)清除輻射損傷干細(xì)胞的同一“編程”防衛(wèi)機(jī)制導(dǎo)致了血癌生長(zhǎng)(延伸閱讀：Sci Rep：福島核輻射后 動(dòng)物血液出現(xiàn)異常 )。通過(guò)重編程這一防衛(wèi)機(jī)制，我們或許能夠在全身輻射之后防止癌癥。

This antibody and human immunoglobulin lambda light chain reaction, and kappa light chain no cross-reaction. B lymphocytes and plasma cells with a lambda light chain can be studied. Extracellular immunoglobulin lambda light chains can also be colored, and care should be taken to distinguish them. Studies suggest that the common feature of B-lymphoblastic tumors is limited to the expression of a single light chain, so kappa and lambda light chains can be used in the study of benign and malignant lymphopathies (reactive lymphoproliferation and lymphoma).

Dr. Wright said: "At this point, the use of omerase to integrate toxic products into omeres is very encouraging."
Importantly, and many other different omerase inhibiting compound, the researchers did not treat the blood of mice in the 6-thiodG, liver and kidney were observed serious side effects.
Dr. Shay said: "Because omerase is expressed in almost all human tumors, this work presents a potentially innovative approach, targeting cancer cells express omerase, and toxicity to normal cells smaller. We believe that such small molecules will fill an unmet need for cancer in an unknown area and will be rapidly applied to the clinic. "
Our body has evolved ways to get rid of defective stem cells. Researchers from the University Cancer Center in Colorado in a study published in the (Stem Cells) magazine "stem cell" is disclosed, one of which way is by "reprogramming" such that the radiation damage of stem cells into no longer be able to long-term survival Other cells. Radiation can cause stem cells to lose their "dryness." This does make sense: You do not want damaged stem cells to stay there to create damaged cells.
The study also confirmed that the same clear "programming" defense mechanism of radiation damage stem cells resulted in the growth of blood cancer (Further reading: Sci Rep: After the Fukushima nuclear radiation abnormal animal blood) when subjected to whole body radiation. By reprogramming this defense mechanism, we may be able to prevent cancer after systemic radiation.